225 related articles for article (PubMed ID: 20104011)
21. [A case of completely responding stage D2 prostatic cancer with no evidence of disease 14 years after diagnosis].
Tsuzuki M; Kawakami S; Yonese J; Ueda T; Kageyama S; Yamauchi T; Kawai T
Hinyokika Kiyo; 1994 Sep; 40(9):837-40. PubMed ID: 7801848
[TBL] [Abstract][Full Text] [Related]
22. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
[TBL] [Abstract][Full Text] [Related]
23. Implications of androgen-deprivation therapy in patients with prostate cancer: A case study.
Doyle-Lindrud S
Clin J Oncol Nurs; 2006 Oct; 10(5):565-6. PubMed ID: 17063610
[TBL] [Abstract][Full Text] [Related]
24. [A case of primary transitional cell carcinoma of the prostate].
Morikawa H; Cho M; Takada S; Fujimoto K; Uemura H; Ozono S; Hirao Y; Natsume O
Hinyokika Kiyo; 2003 Jun; 49(6):357-60. PubMed ID: 12894737
[TBL] [Abstract][Full Text] [Related]
25. [Prostatic carcinoma that arose with hearing loss: a case report].
Sakuma T; Yoshida T; Ohashi H; Nishimura K; Kawano K
Hinyokika Kiyo; 2007 Jun; 53(6):413-6. PubMed ID: 17628942
[TBL] [Abstract][Full Text] [Related]
26. [Luteinizing hormone-releasing hormone for prostate cancer in a hemodialysis patient: a case report].
Mizusawa H; Kontani K; Okaneya T; Yoneyama T
Hinyokika Kiyo; 1997 Jun; 43(6):421-3. PubMed ID: 9250492
[TBL] [Abstract][Full Text] [Related]
27. Tumor control outcomes of patients treated with trimodality therapy for locally advanced prostate cancer.
Copp H; Bissonette EA; Theodorescu D
Urology; 2005 Jun; 65(6):1146-51. PubMed ID: 15922433
[TBL] [Abstract][Full Text] [Related]
28. Case records of the Massachusetts General Hospital. Case 16-2011. A 67-year-old man with recurrent prostate cancer.
Smith MR; Zietman AL; Finkelstein JS; Wu CL
N Engl J Med; 2011 May; 364(21):2044-51. PubMed ID: 21612474
[No Abstract] [Full Text] [Related]
29. Biochemical response after 3-d conformal radiotherapy of localized prostate cancer to a total dose of 66 gy 4-year results.
Wachter-Gerstner N; Wachter S; Goldner G; Nechvile E; Pötter R
Strahlenther Onkol; 2002 Oct; 178(10):542-7. PubMed ID: 12386785
[TBL] [Abstract][Full Text] [Related]
30. [A case of dermatomyositis associated with prostatic carcinoma: a case report].
Sekine Y; Kubota Y; Kurihara J
Hinyokika Kiyo; 2004 Feb; 50(2):95-7. PubMed ID: 15101164
[TBL] [Abstract][Full Text] [Related]
31. [Endometrioid adenocarcinoma of the prostate: report of 3 cases].
Uemura M; Nakagawa M; Kanno N; Nishimura K; Miyoshi S; Kawano K
Hinyokika Kiyo; 2004 Nov; 50(11):825-8. PubMed ID: 15628548
[TBL] [Abstract][Full Text] [Related]
32. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
Soga N; Onishi T; Arima K; Sugimura Y
Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
[TBL] [Abstract][Full Text] [Related]
33. Does small-cell phenotype predict the natural history of prostate cancer? A case study in disease behavior.
Slovin SF
Nat Clin Pract Oncol; 2007 Sep; 4(9):551-4. PubMed ID: 17728713
[TBL] [Abstract][Full Text] [Related]
34. Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy.
Bruchovsky N; Klotz L; Crook J; Goldenberg SL
Cancer; 2007 Mar; 109(5):858-67. PubMed ID: 17265527
[TBL] [Abstract][Full Text] [Related]
35. Discovery of a pituitary adenoma following a gonadotropin-releasing hormone agonist in a patient with prostate cancer.
Massoud W; Paparel P; Lopez JG; Perrin P; Daumont M; Ruffion A
Int J Urol; 2006 Mar; 13(3):303-4. PubMed ID: 16643633
[TBL] [Abstract][Full Text] [Related]
36. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
Sato N; Akakura K; Isaka S; Nakatsu H; Tanaka M; Ito H; Masai M;
Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491
[TBL] [Abstract][Full Text] [Related]
37. [A case of prostate cancer with cyst formation].
Ishida K; Kubota Y; Takada T; Yamada T; Nakano M; Takahashi Y; Ishihara S; Deguchi T
Hinyokika Kiyo; 2003 Apr; 49(4):235-7. PubMed ID: 12784721
[TBL] [Abstract][Full Text] [Related]
38. [A case of prostatic small cell carcinoma].
Hashimoto Y; Kimura G; Tsuboi N; Akimoto M
Hinyokika Kiyo; 2000 Jun; 46(6):425-7. PubMed ID: 10934615
[TBL] [Abstract][Full Text] [Related]
39. [Prostate cancer with high serum level of CEA and CA19-9: a case report].
Momma T; Kimura S; Saito S; Onoda N
Hinyokika Kiyo; 1998 Mar; 44(3):187-91. PubMed ID: 9589883
[TBL] [Abstract][Full Text] [Related]
40. Relapsed prostate cancer with neuroendocrine differentiation and high serum levels of carcinoembryonic antigen without elevation of prostrate-specific antigen: a case report.
Kinebuchi Y; Noguchi W; Irie K; Nakayama T; Kato H; Nishizawa O
Int J Urol; 2007 Feb; 14(2):147-9. PubMed ID: 17302572
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
